NRXS (Neuraxis) Short Interest


NRXS Neuraxis Inc NRXS
42 GF Score
Price $7.27
GF Value $2.92
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Neuraxis Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NRXS vs PYPD, INO, FBIO: Short Interest Comparison

For the Biotechnology subindustry, Neuraxis's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuraxis Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuraxis's Short Interest distribution charts can be found below:

* The bar in red indicates where Neuraxis's Short Interest falls into.


NRXS
42GF Score
Neuraxis Inc NRXS
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Neuraxis (NRXS) Overvalued in 2026?

Based on GuruFocus' analysis, Neuraxis stock appears to be overvalued. The current stock price of $7.27 is trading 149% above its estimated GF Value™ of $2.92. GuruFocus considers Neuraxis to be Significantly Overvalued.

Key valuation signals for NRXS:

  • Short Interest:
  • GF Value™: $2.92 vs. price of $7.27 (149% above fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the NRXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuraxis Business Description

Address 11611 North Meridian Street, Suite 330, Carmel, IN, USA, 46032
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
42GF Score

Get the complete analysis for NRXS

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.27
Price
$2.92
GF Value